Drug Trial Radar · NCT02665065
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Last checked: Nov 19, 2026Latest source record: Jul 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
153
Actual
Start
Jun 2016
Primary completion
Jun 2022
Study completion Dec 2026
Sponsor
- Lead sponsor
- Actinium PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jan 27, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia (AML).
Conditions
- Acute Myeloid Leukemia
- Leukemia, Acute Myeloid
- Myeloid Leukemia, Acute
- Leukemia, Myeloid, Acute
- Acute Myelogenous Leukemia
- Leukemia, Acute Myelogenous
- Myelogenous Leukemia, Acute
- AML
- Bone Marrow Transplant
Interventions
Iomab-BDrug
Conventional CareDrug
HCTProcedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Durable Complete Remission (dCR)Time frame: 6 months from time of initial CR or CRp
Locations
24 sites in 2 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
Yale Cancer Center
New Haven, Connecticut
Georgetown University Medical Center
Washington D.C., District of Columbia
Mayo Clinic
Jacksonville, Florida
Loyola University Medical Center
Maywood, Illinois
University of Iowa
Iowa City, Iowa
The University of Kansas Cancer Center
Westwood, Kansas
Mayo Clinic
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
Roswell Park Cancer Institute
Buffalo, New York
Weill Cornell Medicine
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Stony Brook University
Stony Brook, New York
University of North Carolina Hospital
Chapel Hill, North Carolina
University Hospital of Cleveland Seidman Cancer Center
Cleveland, Ohio
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Oregon Health & Science University
Portland, Oregon
Baylor Charles A. Sammons Cancer Center
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Fred Hutchinson Cancer Research Center
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
University of Ottawa
Ottawa, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.